Archives: Agenda

• Control costs in rare disease clinical trials by tackling complexity and uncertainty head-on
• Optimize site and country selection to reduce startup delays and unnecessary costs
• Streamline vendor management with clear oversight and performance-driven partnerships
• Leverage operational efficiencies (monitoring strategies, data management, patient engagement)
• Maintain quality and patient focus while optimizing financial sustainability

GlobalData’s clinical trials data indicates that new trials initiated in H1 2025 has increased significantly over previous years. In addition to surprising Wall Street, this has shaken up the biopharma competitive landscape and created major opportunities for CROs, CDMOs, Pharma Tech, and consultancies. Behind the headlines, clinical trial reporting lags, shifting start dates, and withdrawals make it easy to miss where the real growth is happening.

This session breaks down what drove the surge, where the next wave is coming from, and how early signals can give you the edge on predicting future market shifts. Whether you run trials, manufacture at scale, or advise life sciences companies, this is about being prepared, before your competitors are.